FERRING-PHARMACEUTICALS
30.10.2015 15:44:05 CET | Business Wire | Press release
Ferring Pharmaceuticals announced today that the filing for the Marketing Authorisation Application for REKOVELLE® (follitropin delta) has been accepted for review by the European Medicines Agency (EMA). REKOVELLE is a novel human recombinant follicle-stimulating hormone (rhFSH) intended for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) therapy such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).1-3 The submission is supported by comprehensive data from the Phase 3 ESTHER trials (E vidence-based S timulation T rial with H uman rFSH in E urope and R est of World) involving 1,326 patients from 37 fertility clinics in 11 countries.2,3
If approved, REKOVELLE would be administered in an individualised dosing regimen according to both the measurement of the woman’s serum anti-Müllerian hormone (AMH), a biomarker that assesses ovarian reserve and predicts ovarian response to stimulation, as well as her body weight. Fertility specialists would assess each patient’s biomarker profile and characteristics, and prescribe a precise fixed daily dose of REKOVELLE from the start of stimulation. This approach of controlled ovarian stimulation with an individualised REKOVELLE dosing regimen was prospectively studied in the ESTHER-1 trial.2 If approved, REKOVELLE would be paired with the recently launched fully-automated Elecsys® AMH immunoassay from Roche4 .
Personalised treatment is a new approach to the management of fertility treatment, with the ultimate goal of helping couples to conceive in an efficient and safe manner.1,5,6,7,8
“Ferring Pharmaceuticals has a long heritage in reproductive health and the acceptance of the Marketing Authorisation Application filing for REKOVELLE in controlled ovarian stimulation represents our commitment to innovation and advancing the role of personalised medicine in the area of fertility,” commented Per Falk, MD, PhD, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals.
- ENDS -
About REKOVELLE (follitropin delta)
REKOVELLE (also known as FE 999049) is the first human recombinant follicle stimulating hormone derived from a human cell line that has been developed for individualised dosing using a companion anti-Müllerian hormone (AMH) diagnostic immunoassay.2 REKOVELLE is a New Molecular Entity (NME) which is clinically distinct1,9 from other follitropins and is not a biosimilar.
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com .
About the Elecsys ® AMH immunoassay from Roche
The Elecsys® AMH immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.10-15 The fully automated Elecsys® AMH immunoassay determines AMH levels in 18 minutes, making it appropriate for routine clinical use and providing clinical confidence in the reliable assessment of ovarian reserve.10-15
REKOVELLE is a trade mark of Ferring B.V., registered in the European Union and under examination elsewhere.
ELECSYS® is a trademark of Roche. All other trademarks are the property of their respective owners.
References
1. Arce J-C, Nyboe Andersen A, Fernandez Sanchez M, et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone–stratified, dose–response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection Fertil Steril. 2014 Dec;102(6):1633-40.
2. ESTHER-1 trial. www.clintrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT01956110 . Last accessed: October 2015.
3. ESTHER-2 trial. www.clintrials.gov . Available at: https://clinicaltrials.gov/ct2/show/NCT01956123 . Last accessed: October 2015.
4. Deeks ED. Elecsys® AMH assay: a review in anti-Müllerian hormone quantification and assessment of ovarian reserve. Mol Diagn Ther 2015; 19: 245-249.
5. Leader B, Baker VL. Maximizing the clinical utility of antimullerian hormone testing in women’s health. Curr Opin Obstet Gynecol 2014;26:226–236.
6. Fleming R, Broekmans F, Calhaz-Jorge C, et al. Can anti-Mullerian hormone concentrations be used to determine gonadotropin dose and treatment protocol for ovarian stimulation? Reproductive BioMedicine Online 2013;26:431–439.
7. Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009 Apr;24(4):867-75.
8. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16:113–130.
9. Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol 2014;54(11):1299-307.
10. Roche Diagnostics. Elecsys® AMH (anti-Mullerian hormone): Method sheet. 2015. https://pim-eservices.roche.com . Last accessed October 2015.
11. Gassner D, Jung R. First fully automated immunoassay for anti-Müllerian hormone. Clin Chem Lab Med. 2014;52(8):1143-52.
12. Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril. 2015;103(4):1074–80.e4.
13. Deeks, ED. Elecsys® AMH Assay: a review in anti-Müllerian hormone quantification and assessment of ovarian reserve. Mol Diagn Ther 2015; 19:245-249.
14. Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent antimüllerian hormone assays. Fertil Steril. 2015 Oct;104(4):1016-1021.e6.
15. Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. Reprod Biol Endocrinol. 2015 Sep 22;13(1):107.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151030005609/en/
Contact:
Ferring Pharmaceuticals
Nicole Barraud-Estoppey
Tel. +41 (0)
58 301 00 53
nicole.barraud-estoppey@ferring.com
or
Helen
Gallagher
Tel. +41 (0) 58 301 00 51
helen.gallagher@ferring.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Expands Nintendo Switch 2 Accessories Ecosystem With New Charging Grip and Travel Bag4.6.2026 18:00:00 CEST | Press release
Following the January debut of Charging Case Pro, Belkin broadens its gaming portfolio with new ways to power, carry, and play Today, Belkin, a leading consumer electronics brand for 40 years, announced the expansion of its Nintendo Switch 2 accessories ecosystem with the launch of the GamingCharging Grip for Nintendo Switch 2 and Gaming Travel Bag for Nintendo Switch 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604082278/en/ Belkin expands Nintendo Switch 2 accessories ecosystem with new Charging Grip and Travel Bag Following the January debut of the award-winning Charging Case Pro, the new accessories build on Belkin’s growing gaming portfolio, offering players more ways to power, protect and carry their gaming essentials wherever they play. After entering the gaming accessories category in June 2025, Belkin continues to expand its ecosystem with thoughtfully designed products that combine premium materials, practi
DEWA Opens Registration for WETEX 20264.6.2026 17:55:00 CEST | Press release
Dubai Electricity and Water Authority (DEWA) has opened registration for the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX), which will take place from 20 to 22 October 2026 at the Dubai World Trade Centre. One of the leading specialised exhibitions of its kind in the world and the largest in the region, WETEX is convened by DEWA under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604642265/en/ DEWA opens registration for WETEX 2026 (Photo: AETOSWire) WETEX covers a wide range of sectors, including energy, water, environment, green development, digital transformation, artificial intelligence (AI), sustainability, decarbonisation, green mobility, green hydroge
LotusFlare’s DNO™ Cloud Powers the Launch of Pi in South Africa4.6.2026 17:49:00 CEST | Press release
LotusFlare, a leading provider of cloud-native, AI-driven digital commerce and monetization platforms for communications service providers (CSPs), today announced its partnership with MTN South Africa to power the launch of its new digital brand, Pi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604149542/en/ At the core of Pi is LotusFlare’s DNO™ Cloud—a fully digital, cloud-native BSS platform that enables delivering a seamless, app-first customer experience at scale. From onboarding to plan management, Pi customers can access 5G mobile, fixed wireless, and travel eSIM services within minutes—without contracts, credit checks, or call centres—through a single, intuitive interface. DNO™ Cloud underpins the entire Pi ecosystem, including front-end digital experiences, product catalog, order management, converged charging, billing, and eSIM orchestration. Deployed on public cloud infrastructure in compliance with South Afr
INRIX Sets the Standard for Predictive and Accurate Parking Intelligence4.6.2026 17:42:00 CEST | Press release
INRIX now has the most parking data in the industry covering 22K cities and 48M spaces INRIX, Inc., a global leader in transportation intelligence, today announced a significantly expanded deployment of its predictive parking and curb intelligence platform, reinforcing its position as the industry’s most comprehensive and decision-grade parking intelligence solution for automotive OEMs, cities, and mobility platforms worldwide. INRIX provides real world coverage based on how parking actually works on-street, off-street, dynamic availability and driver behavior. Others count locations. INRIX understands parking ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604808273/en/ Parking Intelligence for a New Era of Mobility Parking Intelligence for a New Era of Mobility Parking data has traditionally been evaluated based on volume, how many locations are listed, or how many attributes are captured. But as mobility evo
Steady concentration PD with the Carry Life UF system increased ultrafiltration nearly threefold and sodium removal nearly tenfold vs 2.5% dextrose CAPD, while improving glucose efficiency and supporting enhanced fluid management in PD patients4.6.2026 16:45:00 CEST | Press release
Triomed AB today announced positive results from a prospective, multicenter, randomized, crossover study evaluating steady concentration peritoneal dialysis using the Carry Life UF system in adult patients undergoing CAPD. The study demonstrated significant improvements in ultrafiltration, peritoneal sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume in relation to glucose absorption) compared with standard 2.5% dextrose CAPD in the home setting over four weeks. The study results were presented as a Focussed Oral presentation based on a late-breaking clinical trial abstract at the European Renal Association (ERA) Congress in Glasgow, United Kingdom, and simultaneously published in the Journal of the American Society of Nephrology (JASN). In this study, participants received their standard CAPD treatment during the control arm, whereas in the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced by a Carry Life UF treatment three days per week, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom